"Merck on Thursday announced that its blockbuster PD-1 inhibitor Keytruda (pembrolizumab) fell short of its dual primary endpoints in the Phase III KEYLYNK-006 trial, unable to significantly improve survival outcomes in specific patients with metastatic non-squamous non-small cell lung cancer." the article says.
https://www.biospace.com/article/merck-s-keytruda-continues-losing-streak-in-nsclc-with-phase-iii-flop/?utm_campaign=Daily%20Social%20%7C%20News&utm_content=286824601&utm_medium=social&utm_source=linkedin&hss_channel=lcp-424124
bisantrene could be Keytruda's saviour...
Industry news, page-1660
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.100(6.45%) |
Mkt cap ! $274.5M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.75 | $1.61 | $687.0K | 410.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3047 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 18354 | 2 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.67 |
Change
0.100 ( 8.61 %) |
||||
| Open | High | Low | Volume | ||
| $1.64 | $1.73 | $1.63 | 33428 | ||
| Last updated 15.54pm 14/05/2024 ? | |||||
| RAC (ASX) Chart |